

Can Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11908725/publications.pdf>

Version: 2024-02-01

25
papers

720
citations

430874

18
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

1213
citing authors

#	ARTICLE	IF	CITATIONS
1	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. <i>Nature Communications</i> , 2017, 8, 15102.	12.8	88
2	Catalytic Site-Selective Acylation of Carbohydrates Directed by Cation- π Interaction. <i>Journal of the American Chemical Society</i> , 2017, 139, 4346-4349.	13.7	75
3	Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. <i>Journal of Endocrinology</i> , 2013, 217, 185-196.	2.6	55
4	Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor ⁺ Cells in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 716-727.	4.7	49
5	Chiral Catalyst-Directed Dynamic Kinetic Diastereoselective Acylation of Lactols for <i>De Novo</i> Synthesis of Carbohydrate. <i>Organic Letters</i> , 2015, 17, 5272-5275.	4.6	43
6	Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in the Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats after Oral Administration. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1702-1710.	3.3	33
7	A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts. <i>Pharmaceutical Research</i> , 2018, 35, 174.	3.5	33
8	Hyperammonemia enhances the function and expression of P-glycoprotein and Mrp2 at the blood-brain barrier through $\text{NF-}\kappa\text{B}$. <i>Journal of Neurochemistry</i> , 2014, 131, 791-802.	3.9	30
9	Mechanism of activation for the sirtuin 6 protein deacylase. <i>Journal of Biological Chemistry</i> , 2020, 295, 1385-1399.	3.4	30
10	A Mechanistic Physiologically Based Pharmacokinetic-Enzyme Turnover Model Involving both Intestine and Liver to Predict CYP3A Induction-Mediated Drug-Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2819-2836.	3.3	29
11	Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1215-1225.	6.1	27
12	Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1342-1351.	3.4	27
13	Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. <i>Clinical Pharmacokinetics</i> , 2015, 54, 179-193.	3.5	25
14	Acute liver failure impairs function and expression of breast cancer-resistant protein (BCRP) at rat blood-brain barrier partly via ammonia-induced ROS - $\text{ERK}1/2$ activation. <i>Journal of Neurochemistry</i> , 2016, 138, 282-294.	3.9	25
15	Increased Levels of Fatty Acids Contributed to Induction of Hepatic CYP3A4 Activity Induced by Diabetes - In Vitro Evidence From HepG2 Cell and Fa2N-4 Cell Lines. <i>Journal of Pharmacological Sciences</i> , 2014, 124, 433-444.	2.5	24
16	P-glycoprotein and multidrug resistance-associated protein 2 are oppositely altered in brain of rats with thioacetamide-induced acute liver failure. <i>Liver International</i> , 2013, 33, 274-282.	3.9	20
17	Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 792-805.	6.1	19
18	High-fat diet enhanced retinal dehydrogenase activity, but suppressed retinol dehydrogenase activity in liver of rats. <i>Journal of Pharmacological Sciences</i> , 2015, 127, 430-438.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2. <i>Xenobiotica</i> , 2016, 46, 875-881.	1.1	17
20	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 346-355.	6.4	16
21	Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. <i>Xenobiotica</i> , 2012, 42, 709-718.	1.1	13
22	Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 153-164.	4.3	10
23	Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats. <i>Xenobiotica</i> , 2017, 47, 20-30.	1.1	5
24	Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. <i>Frontiers in Immunology</i> , 2021, 12, 748768.	4.8	4
25	Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution. <i>Xenobiotica</i> , 2015, 45, 794-802.	1.1	3